- Home
- SAIA vs MDGL Comparison
SAIA vs MDGL Comparison
Compare SAIA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIA
- MDGL
- Stock Information
- Founded
- SAIA 1924
- MDGL 2011
- Country
- SAIA United States
- MDGL United States
- Employees
- SAIA N/A
- MDGL N/A
- Industry
- SAIA Trucking Freight/Courier Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- SAIA Industrials
- MDGL Health Care
- Exchange
- SAIA Nasdaq
- MDGL Nasdaq
- Market Cap
- SAIA 7.3B
- MDGL 6.1B
- IPO Year
- SAIA 2002
- MDGL N/A
- Fundamental
- Price
- SAIA $256.40
- MDGL $285.73
- Analyst Decision
- SAIA Buy
- MDGL Strong Buy
- Analyst Count
- SAIA 18
- MDGL 9
- Target Price
- SAIA $371.28
- MDGL $420.63
- AVG Volume (30 Days)
- SAIA 703.5K
- MDGL 291.4K
- Earning Date
- SAIA 07-25-2025
- MDGL 08-06-2025
- Dividend Yield
- SAIA N/A
- MDGL N/A
- EPS Growth
- SAIA N/A
- MDGL N/A
- EPS
- SAIA 11.99
- MDGL N/A
- Revenue
- SAIA $3,241,874,000.00
- MDGL $317,383,000.00
- Revenue This Year
- SAIA $3.18
- MDGL $286.17
- Revenue Next Year
- SAIA $7.34
- MDGL $64.17
- P/E Ratio
- SAIA $21.49
- MDGL N/A
- Revenue Growth
- SAIA 8.95
- MDGL N/A
- 52 Week Low
- SAIA $229.12
- MDGL $200.63
- 52 Week High
- SAIA $624.55
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- SAIA 42.44
- MDGL 48.91
- Support Level
- SAIA $256.08
- MDGL $275.00
- Resistance Level
- SAIA $268.54
- MDGL $303.45
- Average True Range (ATR)
- SAIA 9.78
- MDGL 10.81
- MACD
- SAIA 1.37
- MDGL 1.70
- Stochastic Oscillator
- SAIA 32.46
- MDGL 49.02
About SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.